INTERNATIONAL EXHIBITION OF PHARMA AND HEALTHCARE
8th May at Taj Diplomatic Enclave, 9-10th May at Pragati Maidan
     
Back

ALBERT DAVID LTD

15,CHITTARANJAN AVENUE
033-22373900

Product Categories

Formulations
Vitamins/Minerals,Dermatology,Others(Please Specify) [IV Fluids],Anti-Infectives,Opthalmic/Ontological,Gunaecological,Pain/Analgesics,Sex Stimulants/Rejuventators,Nutraceuticals
Medical Devices
Nutraceuticals

Company Profile

Albert David Limited (A brief introduction about ourselves) THE company has been active on the Indian pharmaceutical map since more than eight decades. Having made a modest start in the year 1924 with a single manufacturing facility, today, the company is ranked among the first fifty companies out of more than fifteen thousand active pharmaceutical manufacturers in the country. With an Annual Sales Turnover of approximately USD 50 million for the year ended March 2011, the company continues to maintain a growth significantly higher than the industry average. The company is a part of the Kolkata based industrial House of Kothari’s with current Annual Sales Turnover of USD 400 millions with diversified interests in the manufacture of textiles, engineering items and industrial chemicals, tea plantations, salt processing and international trading. The group also has professional expertise in running modern, multi - divisional hospitals and at present it owns two large hospitals in the country. Some of the group companies have collaborations with well known corporations of U.K., Germany, Japan and U.S.A. Albert David Ltd is a professionally managed and technically well equipped company backed by effective research. Our core competence lies in the manufacture of pharmaceutical finished dosage forms and bulk drugs, infusion solutions, disposable syringes, needles and dosage forms based on herbs at our three different manufacturing units located in the country (viz., Calcutta, Ghaziabad - near New Delhi, Mandideep - near Bhopal respectively), adhering to WHO prescribed GMP standards. Additionally quite a few dosage forms are being outsourced on contract manufacturing basis from several manufacturers in different parts of the country. Our plants at Ghaziabad – near Delhi and Mandideep – near Bhopal are accredited to ISO 9002 defining the quality system standards for the facility. Disposable Syringe and Needles manufactured by us comply with the requirements of the directive 93/42/EEC and thus have been allowed to use “CE” mark for these products. Our company has a technical tie-up with the world’s largest manufacturer of amino acids, Ajinomoto Co. Inc. of Japan as also with Roussel Morishita Co. of Japan for manufacturing and marketing a wide range of crystalline Amino Acid Infusion Solutions in India. We also have technical co-operation with M/s. Pharmaplan GmBH of Germany to manufacture Disposable Syringes and Needles. We manufacture a wide-range of intravenous fluids using the latest state-of-the-art Blow - Fill - Seal (BFS) technology from Rommelag AG of Switzerland / Germany. The company has a strong marketing team of about six hundred plus professionally trained and competent sales force. It has a distribution network spanning across the country, consisting of over sixteen hundred stockists’ outlets and over fifteen Sales Depots. ADL is regularly exporting our products to markets in South and West Asia, the European Union, all over Africa as well as the prestigious markets of North, Central and South America. We possess the DMF for two of our bulk drugs, Tolbutamide and Chlorpropamide with the Food and Drugs Administration (FDA) of USA. The manufacturing facility for these products has been inspected and approved by them. Registration dossiers for these two bulk drugs were also submitted to European Directorate for the quality of Medicines (EDQM) for European Certificate of Suitability. We are meeting requirement for the API, Tolbutamide for several consumers in U.K and Europe. We also enjoy the privilege of being registered with the WHO approved list of suppliers. Many of our products are already registered in a number of countries. The company has strategic plans to venture into newer markets and expand its product portfolio thereby enhancing its competitive advantage by delivering very high quality medicines at low costs.